If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Willis Investment Counsel grew its holdings in shares of Exxon Mobil Co. (NYSE:XOM – Free Report) by 0.9% during the fourth ...

Google has released a whole new range of AI-powered research and interactions that simply can't be matched by DeepSeek or OpenAI.

Busy day at Google today: the company rolled out version 2.0 of its Gemini AI assistant (previously announced in December) ...

Gemini 2.0 Flash is the base model that powers the free version of Gemini. It replaces Gemini 1.5 Flash which was released ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Google also released an experimental version of Gemini 2.0 Pro, the company’s flagship model with the best performance for ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...